Skip to content

GRAIL, Inc. GRAL Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Abbott logo
AbbottABT
$116M-59.6%
Guardant Health logo
Guardant HealthGH
$3.65M+375%
Natera, Inc. logo
Natera, Inc.NTRA
$3.86M+610%
Immunome logo
ImmunomeIMNM
$229K+7.5%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$5.03M-7.8%
Erasca, Inc. logo
Erasca, Inc.ERAS
$258.75M+783,991%

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: GRAIL, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s stock issuance proceeds?
GRAIL, Inc. (GRAL) reported stock issuance proceeds of $1.13M in Q4 2025.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.